Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is the most common acquired chronic autoimmune neuropathy. Current treatments for CIDP are non-specific, ineffective in one-third of patients, and do not result in complete remission in most patients. Thus, more effective, mechanism-based therapies are needed, and understanding the immune tolerance defects that result in PNS autoimmunity will enable their development. Studies to date suggest a model in which CD4+ T cells, macrophages, and complement lead to the autoimmune destruction of Schwann cells in the PNS. Our data indicate that Schwann cells unexpectedly undergo changes during autoimmune attack that may expand the inflammatory response. Schwann cells turn on expression of Periostin, a secreted extracellular matrix protein important in chemotaxis of pathogenic macrophages; increase expression of CD49b, an integrin important in binding complement protein C1q; and induce expression of MHC Class II, a molecule required for antigen-presentation to CD4+ T cells. Thus, we hypothesize that Schwann cell-associated changes may promote autoimmunity through increased macrophage recruitment, complement deposition, and CD4+ T cell activation. To test this, we propose to determine whether: i) Schwann cell-specific Periostin expression is sufficient to drive macrophage recruitment and neuropathy development; ii) loss of CD49b in Schwann cells and/or C1q prevents complement activation and protects from neuropathy; and iii) Schwann cell-specific MHCII deficiency dampens CD4+ T cell stimulation and protects against PNS autoimmunity.
These Aims will be tested in CIDP mouse models and patient nerve biopsies. This project takes advantage of complementary expertise of the multiple PI's (Dr. Su in PNS autoimmunity and Dr. Scherer in Schwann cell biology) to elucidate the role of Schwann cells in promoting demyelinating neuropathy. Successful completion of the Aims of this project will pave the way to identifying new targets for mechanism-based immunotherapeutic interventions for CIDP. Additionally, findings from these studies will contribute to a broader understanding of how Schwann cells may amplify inflammation in immune- mediated diseases of the PNS.

Public Health Relevance

CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) is a debilitating condition in which the immune system attacks and kills Schwann cells in the peripheral nervous system (PNS). We have recently found that Schwann cells undergo changes during autoimmune attack that may further stimulate the autoimmune process. We propose to understand how these changes contribute to the development of PNS autoimmunity, which will provide new potential targets for immunotherapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS107851-03
Application #
9998044
Study Section
Cellular and Molecular Biology of Glia Study Section (CMBG)
Program Officer
Nuckolls, Glen H
Project Start
2018-09-30
Project End
2022-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
3
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Allard, Denise E; Wang, Yan; Li, Jian Joel et al. (2018) Schwann cell-derived periostin promotes autoimmune peripheral polyneuropathy via macrophage recruitment. J Clin Invest 128:4727-4741